Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts While using the atypical chemokine receptor ACKR3/